METASTATIC NON-SMALL CELL LUNG CANCER
Clinical trials for METASTATIC NON-SMALL CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC NON-SMALL CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for METASTATIC NON-SMALL CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise in advanced lung cancer trial
Disease control Recruiting nowThis study tests whether adding the drug Dato-DXd to the standard immunotherapy pembrolizumab works better than pembrolizumab alone for people with advanced or metastatic non-small cell lung cancer that has high PD-L1 levels. About 740 adults with non-squamous lung cancer who hav…
Matched conditions: METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated May 16, 2026 21:49 UTC
-
Could less be more? new study tests lower cancer drug doses to cut side effects
Disease control Recruiting nowThis study tests whether giving a lower, less frequent dose of the cancer drug atezolizumab can still control tumors while causing fewer side effects. About 30 adults with advanced lung, liver, skin, or sarcoma cancers will receive the drug alone or with other treatments. Researc…
Matched conditions: METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 16, 2026 21:48 UTC
-
Supercharged immune cells take on advanced cancers in new trial
Disease control Recruiting nowThis study tests an experimental treatment called OBX-115 for people with advanced melanoma or non-small cell lung cancer that has spread or come back. The treatment uses a patient's own immune cells (tumor-infiltrating lymphocytes) that are modified to produce a protein (IL15) t…
Matched conditions: METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE1, PHASE2 • Sponsor: Obsidian Therapeutics, Inc. • Aim: Disease control
Last updated May 16, 2026 21:46 UTC
-
Gentler chemo combo aims to keep older lung cancer patients on treatment longer
Disease control Recruiting nowThis study is for adults aged 70 or older, or those who are frail, with advanced non-small cell lung cancer that has a low PD-L1 score. The goal is to see if using a reduced dose of chemotherapy together with an immunotherapy drug (anti-PD-1) causes fewer side effects that force …
Matched conditions: METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated May 16, 2026 21:41 UTC
-
New drug combo shows promise in Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new oral drug called STC-15, either alone or combined with toripalimab, in people with advanced solid tumors or certain sarcomas (leiomyosarcoma and liposarcoma). The goal is to see if the treatment is safe and can shrink or control tumors. About 107 adults wit…
Matched conditions: METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE1, PHASE2 • Sponsor: STORM Therapeutics LTD • Aim: Disease control
Last updated May 16, 2026 21:41 UTC
-
Radiation boost may extend life in lung cancer that spread to few sites
Disease control Recruiting nowThis study is for people with non-small cell lung cancer that has spread to 1 to 5 other places in the body. It compares standard maintenance therapy alone versus standard maintenance therapy plus targeted radiation to the cancer spots. The goal is to see if adding radiation help…
Matched conditions: METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: Tata Memorial Hospital • Aim: Disease control
Last updated May 16, 2026 21:41 UTC
-
Electric field therapy takes on lung cancer in major new trial
Disease control Recruiting nowThis study tests whether adding a device that delivers electric fields (TTFields) to standard immunotherapy and chemotherapy helps people with advanced non-small cell lung cancer live longer. About 734 adults whose cancer has spread will be randomly assigned to get the device plu…
Matched conditions: METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: NovoCure GmbH • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
Your own immune cells could shrink lung cancer tumors
Disease control Recruiting nowThis study tests a treatment made from your own immune cells (called TILs or LN-145) for advanced lung cancer that has spread. About 170 people with a specific type of lung cancer will receive their own expanded immune cells to see if tumors shrink. The goal is to measure how man…
Matched conditions: METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Iovance Biotherapeutics, Inc. • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
Double-Drug attack: could adding chemo to standard therapy stop lung cancer growth?
Disease control Recruiting nowThis study compares the usual treatment (osimertinib) with a combination of osimertinib plus chemotherapy (carboplatin and pemetrexed) in people with metastatic EGFR-mutant lung cancer who still have detectable cancer DNA in their blood after starting osimertinib. The goal is to …
Matched conditions: METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
Engineered immune cells take on Hard-to-Treat lung cancer
Disease control Recruiting nowThis early-stage trial tests a new treatment for people with a specific type of lung cancer that has spread or come back. The therapy uses the patient's own immune cells, modified to target a protein called folate receptor-alpha (FRa) on cancer cells. Ten participants will receiv…
Matched conditions: METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE1 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
New hope for hard-to-treat lung cancer: targeted combo shows promise
Disease control Recruiting nowThis study tests a drug called adagrasib, alone or with pembrolizumab (an immunotherapy), in people with advanced non-small cell lung cancer that has a specific genetic change (KRAS G12C). The goal is to see if the combination shrinks tumors or delays cancer growth better than st…
Matched conditions: METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE2, PHASE3 • Sponsor: Mirati Therapeutics Inc. • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
New combo therapy aims to outperform standard lung cancer treatment
Disease control Recruiting nowThis study tests whether a new drug, PF-08634404, combined with chemotherapy works better than the current standard treatment (pembrolizumab plus chemo) for adults with advanced non-small cell lung cancer. About 1,410 participants will be randomly assigned to receive either the n…
Matched conditions: METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated May 11, 2026 20:39 UTC
-
New hope for rare lung cancer mutation: phase 3 trial launches
Disease control Recruiting nowThis study tests a new drug called firmonertinib against two standard drugs (osimertinib or afatinib) as a first treatment for people with advanced non-small cell lung cancer that has certain rare gene changes (EGFR PACC mutations). About 480 participants worldwide will be random…
Matched conditions: METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: ArriVent BioPharma, Inc. • Aim: Disease control
Last updated May 05, 2026 11:56 UTC
-
New targeted drug enters human testing for hard-to-treat lung cancer
Disease control Recruiting nowThis early-stage study tests a new drug called BBO-8520 in about 350 adults with advanced non-small cell lung cancer that has a specific genetic change (KRAS G12C). The main goals are to check safety and find the right dose, while also seeing if the drug shrinks tumors. Participa…
Matched conditions: METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE1 • Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) • Aim: Disease control
Last updated May 04, 2026 16:23 UTC
-
New hope for lung cancer patients whose current drug stops working
Disease control Recruiting nowThis study tests a new drug called Dato-DXd, given alone or with osimertinib, against standard chemotherapy for people with a specific type of advanced lung cancer (EGFR-mutated) that has gotten worse after osimertinib treatment. About 744 adults will take part to see if the new …
Matched conditions: METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 01, 2026 16:00 UTC